Myasthenia Gravis
Disease, Diagnosis and Management
- 1st Edition - December 1, 2025
- Imprint: Academic Press
- Editors: Bhupendra G. Prajapati, Devesh U. Kapoor, Jaimin R. Shah
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 3 6 6 4 7 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 6 6 4 8 - 2
Myasthenia Gravis: Disease, Diagnosis and Management is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoim… Read more
Purchase options
Myasthenia Gravis: Disease, Diagnosis and Management is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoimmune disease affecting the neuromuscular junction. With contributions from global experts, this book addresses the increasing prevalence of Myasthenia Gravis, reflecting the latest in diagnostic techniques and novel therapies such as complement inhibitors and FcRn antagonists. It aims to support healthcare professionals in delivering optimal care through evidence-based insights and patient-centered approaches. The book is divided into several chapters, beginning with an overview of the pathogenesis and immunoregulatory defects in Myasthenia Gravis. Subsequent chapters cover diagnostic methods, non-immunosuppressive treatments, and biological therapies targeting the immune system. Key topics include the role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) in severe exacerbations, thymectomy, molecular mechanisms, and the potential of hematopoietic stem cell transplants. The book also delves into precision medicine, AI applications, clinical trial considerations, and novel therapeutics like anti-FcRn antibodies. Management strategies for ocular Myasthenia Gravis, and a holistic view of living with the disease are also discussed. Myasthenia Gravis: Disease, Diagnosis and Management is invaluable for healthcare providers, physicians, immunologists, ophthalmologists, rheumatologists, physical therapists, pharmacists, and translators. It offers a modern guide to understanding and managing Myasthenia Gravis, integrating clinical expertise with the latest research to improve patient outcomes.
- Explores pathogenesis, diagnosis, and treatment options for Myasthenia Gravis, providing a complete understanding of the disease
- Highlights cutting-edge therapies like complement inhibitors and FcRn antagonists for improved patient outcomes
- Ensures authoritative and up-to-date information contributed by global experts
- Offers evidence-based strategies for healthcare professionals to optimize Myasthenia Gravis management
- Integrates clinical expertise with patient-centered care for a well-rounded perspective on disease management
Researchers and clinicians interested in the mechanisms and treatment of Myasthenia gravis
1. Introduction to Myasthenia Gravis and Ocular Myasthenia Gravis
2. Diagnosis of Myasthenia Gravis
3. Non-immunosuppressive Treatment of Myasthenia Gravis
4. Biologicals -Monoclonal Antibodies Targeting Immune System for Myasthenia Gravis Treatment
5. Novel Immunotherapies for Myasthenia Gravis
6. Management of Myasthenia Gravis in Severe Exacerbation
7. Role of Thymectomy in Myasthenia Gravis
8. Molecular Mechanisms of Myasthenia Gravis
9. Management of Myasthenia Gravis with Hematopoietic Stem Cell Transplant
10. Precision Medicine in Myasthenia Gravis
11. Application of AI in Management of Myasthenia Gravis
12. Clinical Trial Considerations in Myasthenia Gravis
13. Anti-FcRn Antibodies Based Novel Therapeutics
14. Management of Ocular Myasthenia Gravis
15. Living with Myasthenia Gravis and Future Perspective
2. Diagnosis of Myasthenia Gravis
3. Non-immunosuppressive Treatment of Myasthenia Gravis
4. Biologicals -Monoclonal Antibodies Targeting Immune System for Myasthenia Gravis Treatment
5. Novel Immunotherapies for Myasthenia Gravis
6. Management of Myasthenia Gravis in Severe Exacerbation
7. Role of Thymectomy in Myasthenia Gravis
8. Molecular Mechanisms of Myasthenia Gravis
9. Management of Myasthenia Gravis with Hematopoietic Stem Cell Transplant
10. Precision Medicine in Myasthenia Gravis
11. Application of AI in Management of Myasthenia Gravis
12. Clinical Trial Considerations in Myasthenia Gravis
13. Anti-FcRn Antibodies Based Novel Therapeutics
14. Management of Ocular Myasthenia Gravis
15. Living with Myasthenia Gravis and Future Perspective
- Edition: 1
- Published: December 1, 2025
- Imprint: Academic Press
- Language: English
BP
Bhupendra G. Prajapati
Dr. Bhupendra Gopalbhai Prajapati is a Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India. He is also acting as Adjunct Professor at Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, Thailand. With over 22 years of experience in academia, research, and industry, he specializes in lipid-based formulations, nano/microparticulate drug delivery, and bioavailability enhancement. A recipient of several prestigious awards including the AICTE Young Teacher Award and Ganpat University's Staff Excellence honors, Dr. Prajapati has published over 350 research/review papers, and has contributed to more than 170 book chapters. He actively mentors Ph.D. and PG scholars and serves as editor or section editor for several international publications in pharmaceutical sciences.
Affiliations and expertise
Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India; Adjunct Professor at Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, ThailandDK
Devesh U. Kapoor
Dr. Devesh U. Kapoor is a Professor at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, where he has served since September 2010. He holds a B.Pharm from the University of Rajasthan and an M.Pharm in Pharmaceutics from Rajasthan University of Health Sciences, along with a PhD in pharmaceutical sciences. With 14 years of teaching and administrative experience, Dr. Kapoor has authored over 35 research and review articles in esteemed national and international journals and contributed to several books published by Elsevier, Bentham Science, MDPI, Springer, and Wiley. His research focuses on osmotic drug delivery systems, solid lipid nanoparticles, and microspheres. He has received significant grants for organizing national seminars and faculty development programs. Dr. Kapoor holds three design patents and has delivered over 10 expert talks at various national conferences. He is currently the editor of three international books with prominent publishers.
Affiliations and expertise
Professor, Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, IndiaJS
Jaimin R. Shah
Jaimin R. Shah is the Founder, President, and CEO of Upsilon Innovations and a researcher at the University of California San Diego. With over 14 years of experience in academia and industry, he has been a key member of multiple pharmaceutical startups and has worked on over 80 product development projects. Dr. Shah specializes in innovative drug delivery technologies, focusing on cancer, autoimmune diseases, rare diseases, and regenerative medicine. He has published numerous research papers, co-authored book chapters, and holds multiple patents. His expertise spans various dosage forms, including transdermal, topical, lipid-based systems, ophthalmics, and injectables. Dr. Shah holds a B.Pharm from Gujarat University, an M.S. in Pharmaceutics from Long Island University, and a Ph.D. in Materials Science and Engineering from UC San Diego. He is an active member of AAPS, ACS, AACR, and RSC.
Affiliations and expertise
Founder, President, CEO, Upsilon Innovations, San Diego, CA, USA; Researcher, Department of Chemistry and Biochemistry, School of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA